Salbovent

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Salbovent

Quick Facts: Salbovent (Salbutamol)

Property Description
Active ingredient Salbutamol (INN) / Albuterol (USAN)
Form Inhalation Aerosol, Nebuliser Solution
Pharmacological class Short-Acting beta2-Adrenergic Agonist (SABA), Bronchodilator
General purpose Immediate relief of airway tightening (bronchospasm)
Origin Synthetic organic compound

What Type of Medicine is Salbovent?

Salbovent is a pharmaceutical preparation that utilizes the active ingredient Salbutamol (known in the U.S. as Albuterol), a substance that is clinically recognized as one of the most widely used first-line rescue treatments for airway constriction. It is formally classified as a Short-Acting beta2-Adrenergic Agonist (SABA), positioning it within the functional class of bronchodilators. Salbutamol is a synthetic organic compound, and its established therapeutic importance is highlighted by its inclusion on the WHO Model List of Essential Medicines.

Composition and Available Forms of Salbutamol

The medicinal core is Salbutamol sulfate, typically manufactured as a racemic mixture containing two stereoisomers. The drug is engineered primarily for inhalation, a delivery route intended to provide rapid onset of action directly at the bronchial tubes. Salbovent and similar preparations are often distinguished by the type of delivery device used, most commonly an Inhalation Aerosol (metered-dose inhaler using a propellant) or a Nebuliser Solution (dissolved in a sterile isotonic solution).

General Purpose and Mechanism of Action

The overall purpose of Salbovent is to achieve the immediate reversal of bronchospasm, or the acute tightening of the muscles around the air passages. Its mechanism relies on Salbutamol's highly selective binding to beta2-adrenoceptors on the bronchial smooth muscle. This activation results in swift bronchodilation, which quickly restores proper airflow. For instance, during an unexpected onset of chest tightness, this rapid-action mechanism provides timely relief as a fast-acting rescue medication.

Regulatory References

  1. WHO Model List of Essential Medicines

What side effects are possible with Salbovent?

Possible side effects and safety information

The safety profile of Salbovent (Salbutamol/Albuterol) is based on adverse reactions formally documented in official regulatory sources. These effects are classified by frequency and the body system affected.

Frequency-Classified Adverse Reactions

The most Common adverse reactions documented in regulatory sources include tremor, headache, tachycardia (increased heart rate), and throat irritation. Effects classified as Uncommon include palpitations and muscle cramps. Rare adverse reactions documented are hypokalemia (low serum potassium), peripheral vasodilatation, and serious hypersensitivity reactions such as angioedema. Events classified as Very Rare include cardiac arrhythmias (such as atrial fibrillation) and paradoxical bronchospasm.


Systemic and Serious Safety Notes

The adverse reactions primarily involve the Nervous System (e.g., tremor, headache) and the Cardiovascular System (e.g., tachycardia, palpitations), reflecting the systemic effects of the medicine. Hypokalemia is listed under Metabolism and Nutrition Disorders.

Serious Adverse Reactions officially documented include the rare, life-threatening occurrence of paradoxical bronchospasm, which is an acute, sudden increase in wheezing that requires immediate discontinuation. Immediate hypersensitivity reactions, including anaphylaxis, are also listed. Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs, as noted in official labeling.

Safety constraints advise caution for patients with pre-existing conditions such as cardiovascular disorders (hypertension, coronary insufficiency), diabetes mellitus, and hyperthyroidism. The regulatory label notes that paradoxical bronchospasm may frequently occur with the first use of a new inhaler.

Overdose and Emergency Response

The regulatory documentation for Salbovent (Salbutamol/Albuterol) provides specific guidance on the manifestations of overdose and when urgent medical help must be sought.

Overdose is primarily characterized by an exaggeration of expected pharmacological effects, which include tachycardia, palpitations, tremor, headache, peripheral vasodilatation, and pronounced tenseness. Severe outcomes officially documented in regulatory labels focus on metabolic and cardiac risks. These include serious cardiac arrhythmias and significant metabolic disturbances such as hypokalaemia (abnormally low serum potassium) and lactic acidosis. Fatalities have been reported in association with excessive use of sympathomimetic inhalers.

When to Seek Immediate Help

Immediate medical attention must be sought for any suspected overdose. Additionally, patients are mandated to seek urgent medical advice if their usual relief from the medication is diminished or the duration of action is reduced, as this may signal a deteriorating condition.

In the event of an overdose, management typically involves supportive care and monitoring. Officials note that a cardioselective beta-blocking agent is the preferred antidote, though its administration requires extreme caution in patients with a history of bronchospasm. Monitoring of serum potassium levels and observation for metabolic acidosis are required steps in the clinical management documented by regulators.

Therapeutic Uses of Salbovent

What Salbovent Treats: Main Uses and Benefits

Salbovent is generally used to help address symptoms related to acute respiratory distress and sudden airway constriction. It plays a role in managing acute symptomatic episodes and is utilized for the relief of bronchospasm.

The medication is commonly used across conditions characterized by episodic or fluctuating symptom patterns, providing support in acute situations where temporary functional strain or discomfort occurs. This application is relevant for easing key manifestations like wheezing, acute shortness of breath, and debilitating chest tightness across therapeutic domains, including the acute management of asthma attacks, symptomatic episodes in COPD exacerbations, and the prevention of exercise-induced bronchospasm (EIB).

This supportive application provides relief that helps ease the overall symptom burden. It is applied in settings where short-term symptom stabilization is important, supporting patients during difficult episodes.

Quick Reference: Symptom Management

Symptom Group Primary Benefit
Acute Wheezing & Tightness Contributes to improved comfort during periods of heightened symptoms.
Episodic Dyspnea Assists with maintaining functional stability.
Activity-Induced Symptoms Provides supportive relief when symptoms interfere with routine activities.

Regulatory References

  1. NIH MedlinePlus overview of Albuterol

Eligibility and Restrictions for Use

Who Can and Cannot Use Salbovent?


Eligibility Exclusions (Contraindications)

Salbovent is contraindicated and must not be used in patients with a known history of hypersensitivity to Salbutamol (Albuterol) or to any excipient within the specific product formulation. For certain dry powder inhalers, severe milk protein hypersensitivity is an exclusion. Non-intravenous forms of the medicine are also strictly contraindicated for the management of uncomplicated premature labor or threatened abortion, as stated in regulatory documents.


Age and Conditional Restrictions

Safety and efficacy are established for adults and adolescents. For the pediatric population, eligibility is age-dependent: use is established for children 4 years of age and older for inhalation aerosols, and often for children 2 years and older for nebulizer solutions. Use is not established below these respective ages. Use requires caution in patients with pre-existing conditions such as Cardiovascular Disorders (including hypertension and arrhythmias), Diabetes Mellitus, and Hyperthyroidism (Thyrotoxicosis).


Reproductive Status

During pregnancy and lactation, use is conditional. It is only permitted if the potential benefit to the mother is medically determined to outweigh any possible risk to the fetus or infant, as defined by official regulatory guidance.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Salbovent (Salbutamol) is structured around pharmacodynamic effects and specific administration restrictions, as outlined in government regulatory documents.


Documented Interaction Patterns

  • Antagonistic Combinations: Non-selective Beta-blockers (e.g., Propranolol) are documented as blocking the pulmonary effects of Salbovent, which may produce severe bronchospasm. Therefore, these agents should not normally be prescribed together for patients with asthma. The co-administration of other short-acting sympathomimetic aerosol bronchodilators is also not recommended due to the potential for potentiated cardiovascular effects.

  • Potentiation of Hypokalemia: Non-potassium-sparing Diuretics (e.g., Loop or Thiazide diuretics), Xanthine Derivatives, and Corticosteroids may potentiate hypokalemia (low serum potassium levels). This additive effect is noted as a particular caution in contexts such as acute severe asthma.

  • Cardiovascular and Timing Restrictions: Monoamine Oxidase Inhibitors (MAOIs) and Tricyclic Antidepressants (TCAs) may potentiate Salbovent’s action on the vascular system. Administration must be with extreme caution in patients treated with these agents or within two weeks of their discontinuation. Furthermore, Salbovent should generally not be used for at least six hours before the initiation of anaesthesia with Halogenated Anaesthetics due to the expected increased risk of severe dysrhythmia.

  • Exposure Modification: Salbutamol has been documented to cause a decrease in serum digoxin levels when co-administered.

Mechanism of Action

Salbovent is a selective beta2-adrenergic receptor agonist that preferentially targets beta2-adrenoceptors located on the bronchial smooth muscle cells of the airways. Its interaction type is that of an agonist, initiating a specific G-protein-coupled receptor (GPCR) signaling cascade upon binding.

The binding event causes a conformational change that activates the associated Gs protein. This activation, in turn, stimulates the membrane-bound enzyme adenylyl cyclase. Adenylyl cyclase then catalyzes the intracellular conversion of adenosine triphosphate (ATP) into the second messenger cyclic adenosine monophosphate ( cAMP) , significantly increasing its cytoplasmic concentration.

The elevated cAMP level triggers the downstream cascade by activating Protein Kinase A ( PKA). PKA-mediated phosphorylation of various target proteins leads to a reduction in intracellular calcium ion ( Ca^2+) concentration. The decrease in free Ca^2+ inhibits the phosphorylation of myosin light chains, which is an essential step for muscle contraction.

The final system-level physiological consequence of this intracellular pathway is the relaxation of the bronchial smooth muscle fibers, leading to a decrease in airway resistance and modulation of pulmonary airflow dynamics.

Dosage and Administration Information

How to Use Salbovent

Salbovent (Salbutamol/Albuterol) is primarily utilized as an oral inhalation agent, delivered via a metered-dose inhaler or a nebuliser solution, aligning with its function as a short-acting agent. Alternative administration routes, including oral (tablets or syrup) and parenteral (injection), are reserved for specific clinical contexts or severe episodes.

Standard Administration Patterns

The most common use pattern for the inhalation aerosol is for acute relief, typically involving 2 inhalations (180 to 200 micrograms) per single dose. This dose may be repeated every 4 to 6 hours as needed. For prevention, such as before activity, 2 inhalations are administered 15 to 30 minutes prior to the event. The maximum dose for non-acute, self-administered inhalation is generally 8 inhalations over a 24-hour period.

Intermittent nebulisation treatment typically involves administering 2.5 mg to 5 mg of the nebuliser solution per session, administered up to four times a day. Solutions are generally used undiluted, though guidelines allow for dilution with sterile normal saline to extend the administration time if necessary.

Procedural Requirements and Adjustments

Specific procedural requirements must be followed for effective administration. The metered-dose inhaler must be primed with a set number of test sprays (e.g., 4) when first used or if it has been unused for a specified period (e.g., two weeks). The inhaler actuator must also be cleaned weekly to prevent mechanical failure.

For pediatric use, children 4 years and older follow the same 2-inhalation dosing schedule as adults for both rescue and preventive use. In older adults or sensitive patients using oral forms, treatment may commence with a lower initial dose, such as 2 mg three or four times daily, as a precautionary measure. If the required frequency of inhaler use increases, this should be interpreted as a sign of underlying condition deterioration, necessitating clinical re-evaluation.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research has explored whether Salbovent is a viable treatment option, with studies examining its comparative performance against existing treatments. Studies have investigated how Salbovent acts to modulate acute pain and explored the duration of its symptomatic effects.


Safety and Tolerability Profile

Research has explored the tolerability profile of Salbovent in various patient groups. Early phase trials focused on establishing a preliminary safety profile, and most reported adverse events were classified as mild or moderate in severity. Studies have also included evaluations in subjects with mild kidney impairment and hepatic impairment to assess changes in its safety profile.


Efficacy in Pain Management

Clinical trials have evaluated the effects of Salbovent in specific acute and chronic musculoskeletal pain conditions.

Acute Pain Models

Studies evaluated the effects of Salbovent administration over a 10-day period in models such as post-operative dental pain, comparing findings to a placebo and a standard non-opioid analgesic. Trials also explored the use of Salbovent as part of a multi-modal regimen following general orthopedic surgery, and research has examined its potential effect on markers of chronic inflammation.

Chronic Conditions Research

Research has investigated whether Salbovent administration is associated with a lower frequency of symptomatic flare-ups and has assessed its impact on health-related quality of life measures. For Osteoarthritis (OA), studies examined patient-reported pain scores and physical function assessments following administration for 12 weeks. For Fibromyalgia (FM), evidence remains limited; a single Phase 2 study explored changes in the overall disease impact on patients taking Salbovent compared to a comparator group.


Research on Co-administration

Initial findings suggest that the co-administration of Salbovent and Compound-Y was associated with changes in patient-reported outcomes. A limited number of clinical studies have suggested whether the combination therapy is associated with different rates of adverse events compared to monotherapy with Salbovent.

Key Studies & References Exploratory Phase 2 Study of Salbovent in the Management of Fibromyalgia Syndrome

Frequently Asked Questions (FAQ)

Common questions about Salbovent (FAQ)

Q: How quickly does Salbovent start working after it is used?

Salbovent (Salbutamol/Albuterol) is recognized as a fast-acting rescue treatment. Official regulatory documents indicate that the inhalation agent typically begins to open the airways and provide relief within 5 to 6 minutes of use.


Q: How long can the effect of Salbovent be expected to last?

Salbovent is classified as a short-acting bronchodilator. According to official product information, the symptomatic effect of a single dose is generally expected to last for approximately 4 to 6 hours.


Q: What is the difference between Salbovent and a 'preventer' inhaler?

Salbovent is officially classified as a Short-Acting Beta-Agonist (SABA), indicated for the immediate relief of sudden breathing problems. 'Preventer' inhalers (often containing steroids or long-acting medicines) are used daily to help reduce underlying inflammation. Official guidelines related to asthma management indicate that if SABA use alone is insufficient, the addition of an anti-inflammatory agent (preventer) may be considered.


Q: Is Salbovent the same kind of medicine as other quick-relief inhalers?

Yes, Salbovent utilizes Salbutamol (or Albuterol), which is formally classified as a Short-Acting beta2-Adrenergic Agonist (SABA). This classification means it belongs to the same core drug class as other widely utilized medicines for the quick relief of acute airway constriction.


Q: Is Salbovent considered safe for use during pregnancy?

Official regulatory guidance states that the use of Salbutamol during pregnancy is permitted only if the potential benefit justifies the potential risk to the fetus. Decisions regarding its use during pregnancy should be discussed with a healthcare professional.


Q: Can Salbovent be used while breastfeeding?

Official regulatory guidance permits use during lactation (breastfeeding) only if the potential benefit to the mother is medically determined to outweigh any possible risk to the infant.


Q: Is Salbovent suitable for use in children?

Yes, regulatory documentation defines the age ranges for which safety and effectiveness have been determined. For the inhalation aerosol, this is typically for children 4 years of age and older, while nebulizer solutions are often approved for children 2 years and older.


Q: Is there a different appropriate age range for different types of Salbovent products (e.g., nebulizer vs. inhaler)?

Yes, differences are noted in regulatory documentation based on the delivery device. The inhalation aerosol (MDI) is typically established for use in those 4 years and older, while nebulizer solutions may be approved for children as young as 2 years old.


Q: Does Salbovent contain steroids?

No. Salbovent is classified as a Short-Acting beta2-Adrenergic Agonist (SABA) bronchodilator. It is not classified as a corticosteroid and does not contain steroids.


Q: What should I do if I accidentally forget to take a scheduled dose of Salbovent (if it's a regular-use product)?

Official patient information often advises patients not to worry about a forgotten scheduled dose. Instead, they should use the next dose only when it is due or if immediate symptoms occur. The guidance further notes that a double dose should not be used to compensate for a missed dose.


Q: Is it safe to use Salbovent if it has passed its expiration date?

Official instructions specify that the inhaler should be discarded when the dose counter reads zero or 12 months after its removal from the foil pouch, whichever is sooner. Adhering to these instructions helps ensure the device functions as described and the expected amount of medicine is delivered.


Q: Can Salbovent cause a dry or bad taste in the mouth?

Yes, safety information in regulatory documents includes the reporting of unusual or bad taste (taste alteration) and dry or irritated throat as possible effects.


Q: Is there a link between Salbovent use and insomnia or trouble sleeping?

Regulatory documents list central nervous system effects such as restlessness and anxiety as possible side effects. Some official safety information also notes sleeplessness (insomnia) as a less common adverse reaction.


Q: Can I drive or operate machinery after using Salbovent?

Official patient information advises that Salbovent can cause effects like dizziness or shakiness in some people. The recommendation in patient information is to avoid driving or operating machinery until any such effects have subsided.


Q: Can Salbovent cause muscle cramps or pain?

Yes, official safety information lists muscle cramps as an uncommon adverse reaction. In some formulations, generalized musculoskeletal pain has also been reported.


Q: What information should I record in a diary about my Salbovent use?

Patient guidance often suggests keeping a diary to record how often the inhaler is needed for relief. This record can assist in monitoring the consistency of the breathing condition and may inform a healthcare provider if the frequency of use increases.


Q: Does Salbovent affect or interact with birth control pills?

Official patient information generally indicates that Salbutamol is not known to affect hormonal contraception, including combined birth control pills and emergency contraception.


Q: Can Salbovent cause a cough or sore throat?

Yes, official safety documents list cough and throat irritation (oropharyngeal pain) as adverse events reported during the use of Salbutamol/Albuterol products.


Q: Does Salbovent have any potential environmental impact related to its propellant?

Salbovent inhalation aerosols commonly use the propellant HFA-134a (1,1,1,2-tetrafluoroethane) in their formulation description. This propellant was introduced as a replacement for older, ozone-depleting propellants.


Q: Are there different brand names for the same active ingredient in Salbovent?

Yes, the active ingredient in Salbovent is Salbutamol, which is also known internationally as Albuterol in the United States. It is marketed under various brand names depending on the manufacturer and the region.


Q: Can Salbovent affect blood sugar levels?

Yes, regulatory warnings note that Salbutamol, like other medicines in its class, can induce reversible metabolic changes, including increased blood glucose levels. Regulatory documents indicate caution is warranted when the product is used in patients who have diabetes.


Q: Is there a recommended way to dispose of a used Salbovent inhaler?

Official instructions require that the pressurized canister not be thrown into a fire or incinerator because it could burst. The used product must be disposed of in accordance with all applicable local regulations, as specified by official guidance.


Q: Why do some Salbovent formulations have a warning about milk protein sensitivity?

Specific dry powder inhaler (DPI) formulations of the medicine use lactose as an inactive ingredient. Since lactose can contain trace amounts of milk proteins, a known severe milk protein hypersensitivity is listed as a contraindication for those specific products.


Q: Does the device type (e.g., DPI, MDI) change how Salbovent works?

No, the device type, whether it is a metered-dose inhaler (MDI) or a dry powder inhaler (DPI), does not change the fundamental mechanism of action of the active ingredient. The active ingredient still works in the same way to relax the airways.

How should Salbovent be stored and disposed of?

Storage Conditions and Container Requirements

Salbovent (Albuterol Sulfate) Inhalation Aerosol must be stored at controlled room temperature between 20°C and 25°C (68°F and 77°F). It is mandatory to store the product out of the reach and sight of children. The pressurized canister must be protected from extreme heat and must not be exposed to temperatures above 49°C (120°F), which could cause it to burst. The canister must also not be punctured or stored near an open flame.

Stability and Disposal Instructions

The inhaler should be discarded when the dose counter reads zero or 12 months after its removal from the foil pouch, whichever is sooner. When disposing of the unit, it should never be thrown into a fire or incinerator. Disposal of the used or unused product must be done in accordance with all applicable federal, state, and local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Salbovent found in:

A-Z Index: